Donald Trump announced 100% tariffs on imported branded or patented pharmaceutical products from October 1, 2025, unless companies build US manufacturing facilities. This policy primarily impacts European nations exporting high-value drugs, while India’s generic exports may largely be shielded, though “branded generics” classification remains a concern.